| Long-Term Follow-up Results of Living Kidney Donors: 20 Years of Experience | Ahmet AYKAS,Erhan TATAR | 98–102 |
| Hepatitis C Prevalence in Hemodialysis Patients and the Results of New Antiviral Therapy | Neslihan ÇELİK,Onur ÇELİK,Can SEVİNÇ,Onur ÜNAL | 103–108 |
| The Validity of Malnutrition Universal Screening Tool (MUST) for Nutritional Screening in Hemodialysis Patients | Seyit UYAR,Mehmet KÖK,Aysun ÜNAL,Gökhan KÖKER,Süleyman DOLU,Ayça İNCİ,Ayhan Hilmi ÇEKİN | 109–113 |
| Therapeutic Plasma Exchange in Renal Diseases: A Three-Year Retrospective Analysis | Sibel ERSAN,Fatma LİV,Sibel DEMİRAL SEZER,Hülya ÇOLAK,Alper ALP,Cengiz CEYLAN,Harun AKAR | 114–119 |
| Development and Psychometric Testing of the Turkish Immunosuppressive Medication Adherence Scale | Zeliha ÖZDEMİR KÖKEN,Melek Serpil TALAS,Derya GÖKMEN | 120–126 |
| The Effect of Hemodialysis Treatment on Quality of Life and Sleep in Patients with Chronic Kidney Disease | Mustafa DEMİR,Ömer CANPOLAT,Fadime DEMİR,Sedat ÇİÇEK,Ayhan DOĞUKAN | 127–131 |
| Prevalence of Vitamin D Deficiency in Patients with Stage 3/4 Chronic Kidney Disease and Its Relation to Secondary Hyperparathyroidism | Ayşe Selcen PALA,Eda KAYA,Selma ALAGÖZ,Sinan TRABULUS,Murat BOLAYIRLI,Mehmet Rıza ALTIPARMAK,Nurhan SEYAHİ | 132–137 |
| Chronic Renal Failure, Anemia, and Parenteral Iron Treatment: From Bench to Bedside | Mehmet Ası OKTAN,Cihan HEYBELİ,Zahide ÇAVDAR | 138–146 |
| The Possible Association of Chronic Hepatitis B with Renal AA Amyloidosis | Eray EROĞLU,İsmail KOÇYİĞİT,Davut EREN,Aydın ÜNAL,Murat Hayri SİPAHİOĞLU,Hülya AKGÜN,Bülent TOKGÖZ,Oktay OYMAK | 147–149 |
| Convulsion due to Ertapenem in a Renal Transplant Patient | Egemen ŞENEL,Fatma Betül GÜZEL,Ahmet Burak AĞAOĞLU,Selçuk NAZİK,Ertuğrul ERKEN,Orçun ALTUNÖREN,Özkan GÜNGÖR | 150–153 |
| Remembering the Basics: A Patient with Sickle Cell Disease and Proteinuria | Ezgi Pınar ÖZBALAK,Şafak MİRİOĞLU,Ezgi ŞAHİN,Yasemin ÖZLÜK,ALİ RIZA UÇAR,Halil YAZICI,Işın KILIÇASLAN,Sevgi KALAYOĞLU-BEŞIŞIK |